With a market cap of $64.6 billion, Cencora, Inc. (COR) is a leading global pharmaceutical solutions company that partners with pharmaceutical innovators to improve access to therapies and support better health outcomes for people and animals worldwide. The company provides secure, reliable distribution of pharmaceuticals, healthcare products, and related solutions to care providers, helping create healthier futures across the global healthcare industry.
The Conshohocken, Pennsylvania-based company is slated to announce its fiscal Q4 2026 results before the market opens on Wednesday, Nov. 4. Ahead of the event, analysts forecast Cencora to report an adjusted EPS of $4.51, up 17.5% from $3.84 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts project the prescription drug distributor to report adjusted EPS of $17.87, a 11.7% rise from $16 in fiscal 2025.
www.barchart.com Shares of Cencora have risen marginally over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 13.1% increase and the State Street Health Care Select Sector SPDR ETF's (XLV) 22.8% return over the same period.
www.barchart.com Cencora shares rose 3.6% on Aug. 5, after the company beat quarterly earnings and revenue estimates and raised its annual adjusted EPS forecast to $17.75 - $17.95. Q3 2026 adjusted EPS reached $4.48 and revenue rose to $84.75 billion, both beating the consensus, supported by strong specialty medicine and GLP-1 drug demand. Revenue at its largest unit, U.S. Healthcare, increased 4.9% to $74.86 billion, helping ease concerns about specialty drug volumes and GLP-1-related pressures, although the company maintained its annual revenue growth forecast of 4%–6%.
Analysts' consensus rating on COR stock is bullish, with an overall "Strong Buy" rating. Among 14 analysts covering the stock, 10 recommend a "Strong Buy” and four give a "Hold" rating. This configuration is slightly less bullish than three months ago, with 11 analysts suggesting a "Strong Buy."
The average analyst price target is $366.85, indicating a potential upside of 10.8% from the current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Lockheed Vs. RTX: The Cheaper Defense Giant Is The Clear Value Win Why 3M’s Amazon Deal Could Be a Big Game Changer for MMM Stock Ahead of Seagate Earnings, Here's What Barchart Data Says Comes Next for STX Stock SKHY Stock Pops as SK Hynix Scraps Solidigm's U.S. IPO